AxoSim was founded to address unsustainably high clinical failure rates that cost pharmaceutical companies billions of dollars and patients years of waiting for new medications and therapies for serious neurological diseases. An astounding 89% of all new drugs, and 94% of neurological drugs, fail in clinical trials. A key factor driving this dismal failure rate is that animal testing that is an essential part of preclinical drug development cannot predict human results. To us, this is unacceptable when new technologies offer alternatives: researchers, pharmaceutical companies, and patients in need deserve better.
In 2014, AxoSim spun out of Tulane University with a license to proprietary technology with the potential to solve the challenge of modeling human results in vitro. Over a decade of research by our founding scientists led to the development of our Nerve-on-a-Chip® platform that can predict clinical performance in the lab, helping our biopharmaceutical partners develop safer and more effective cures and save millions of dollars and years of development time in the process. We are working to rapidly expand the applications of our platform to address the growing burden of neurodegenerative diseases.
To that end, in 2019, AxoSim announced the acquisition of Organome and exclusively licensed the intellectual property behind Thomas Hartung, MD, PhD’s Mini-Brain platform from Johns Hopkins University, with Dr. Hartung joining AxoSim’s team as the Consulting Vice President of Scientific Affairs. The addition of this powerful platform now enables us to address neurological applications across both the central and peripheral nervous systems. By providing the only two commercially-available platforms with 3D human-relevant myelination, AxoSim is truly at the cutting edge of drug development.
Today, our offices are located in the New Orleans BioInnovation Center, the city’s first LEED Gold-certified laboratory building. This cutting-edge facility in the heart of the downtown BioDistrict positions our company to remain at the forefront of emerging technology and research. We have the facilities and the team to accomplish our goals and to have a fundamental impact on the way neurological drugs are developed.
We believe that our biomimetic platforms can help transform the development of drugs to combat multiple sclerosis, ALS, Alzheimer’s disease, Parkinson’s disease, and other neurological disorders. We are proud that our team is made up of driven, creative individuals, all of whom are passionate about disrupting – and accelerating – the preclinical testing process to speed the development of important new drugs.